ArtiQ
ArtiQ develops AI-based CE-marked Class IIa medical software for automated interpretation of pulmonary function tests and spirometry quality assessment in clinical practice and pharmaceutical respiratory trials. Following its April 2024 acquisition by Clario, ArtiQ serves pulmonologists, primary-care clinicians, and pharma sponsors globally.
- Company typePrivate
- Founded2019
- HeadquartersLeuven, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What ArtiQ does
ArtiQ NV/SA is a Leuven, Belgium-based medical software company founded in 2019 as a spin-off from KU Leuven's University Hospital Leuven, following eight years of respiratory diagnostics research. The company develops AI-first software for pulmonary function test (PFT) interpretation and spirometry quality assessment, addressing both clinical practice and pharmaceutical clinical trial workflows. Its product portfolio comprises ArtiQ.PFT and ArtiQ.Spiro (CE-marked Class IIa medical devices under EU MDR 2017/745 that provide AI-supported interpretation of PFTs and spirometry for pulmonologists, GPs, and primary-care clinicians), ArtiQ.QC (instant deep-learning-based spirometry over-reading for clinical trials, validated at 95% agreement with human experts for FEV1), and ArtiQ.RBM (AI-enabled risk-based monitoring for trial data integrity and site retraining).
ArtiQ monetizes primarily through recurring software subscriptions and per-study licensing to two core customer segments: pulmonologists, respiratory specialists, and primary-care clinicians using ArtiQ.PFT and ArtiQ.Spiro in clinical practice, and pharmaceutical companies (including AstraZeneca, Chiesi, and Boehringer Ingelheim) using ArtiQ.QC and ArtiQ.RBM in respiratory clinical trials. Distribution combines direct enterprise sales, a self-service free trial for ArtiQ.PFT, channel partners (Vyaire Medical across European hospitals and Acertys in Belgium), and — most strategically — embedded OEM integrations with five clinical trial platforms (Clario, NuvoAir, patientMpower, Koneksa, Zephyr) that white-label ArtiQ's AI over-reading within existing trial workflows. The company holds ISO 13485 certification and was acquired by Clario in April 2024, operating since as a wholly-owned subsidiary while retaining its product portfolio and brand identity.
ArtiQ firmographics
Firmographics- Name
- ArtiQ
- Legal name
- ArtiQ NV/SA
- Website
- https://artiq.eu
- Company type
- Private
- Founded year
- 2019
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- ArtiQ develops AI-based CE-marked Class IIa medical software for automated interpretation of pulmonary function tests and spirometry quality assessment in clinical practice and pharmaceutical respiratory trials. Following its April 2024 acquisition by Clario, ArtiQ serves pulmonologists, primary-care clinicians, and pharma sponsors globally.
- Ownership category
- akta.pro rank
ArtiQ industry classification
Industry- Product category
- AI Medical Device Software (Respiratory Diagnostics & Clinical Trials)
- NAICS
- Software Publishers (513210), Software Publishers (51321), Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- Pulmonary Function Testing (PFT) & Respiratory Diagnostics (HLAKANAC), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where ArtiQ is headquartered
LocationHeadquarters
- HQ city
- Leuven
- HQ country
- Belgium
- HQ region
- Europe
Offices2 records
Markets served
ArtiQ business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Software Subscriptions / Licenses (ArtiQ.PFT, ArtiQ.Spiro): ArtiQ offers its AI-powered diagnostic software (ArtiQ.PFT and ArtiQ.Spiro) to medical doctors and hospitals as cloud-based subscriptions. These are CE-marked Class IIa medical devices. The company targets healthcare institutions and pulmonologists who pay for access to the AI interpretation platform.
- Clinical Trial Software (ArtiQ.QC, ArtiQ.RBM): ArtiQ.QC and ArtiQ.RBM are sold to pharmaceutical companies conducting respiratory clinical trials. Revenue is generated through platform integrations with clinical trial eCOA/ePRO systems and per-study licensing. The software is embedded in existing clinical trial platforms, with pharma sponsors paying for AI-based over-reading and risk monitoring services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free trial available for ArtiQ.PFT |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels8 records
ArtiQ product offering
Product offeringCore offering
ArtiQ develops AI-first software solutions for respiratory diagnostics and clinical research. Its product portfolio includes ArtiQ.PFT and ArtiQ.Spiro (CE-marked Class IIa medical devices that provide automated AI interpretation support for pulmonary function tests and spirometry) and ArtiQ.QC and ArtiQ.RBM (AI-based over-reading and risk-based monitoring software for spirometry quality control in pharmaceutical clinical trials). The software is sold to pulmonologists, hospitals, and pharmaceutical companies, and is embedded into clinical trial eCOA/ePRO platforms through integrations with Clario, NuvoAir, Koneksa, patientMpower, and Zephyr.
Product overview
ArtiQ offers a portfolio of AI-first software solutions for respiratory diagnostics and clinical research. The core products include ArtiQ.PFT (cloud-based pulmonary function test interpretation support for medical doctors), ArtiQ.Spiro (spirometry-specific interpretation and quality control), ArtiQ.QC (instant AI-based spirometry over-reading for pharmaceutical clinical trials), and ArtiQ.RBM (AI-enabled risk-based monitoring for clinical trial data integrity). ArtiQ.PFT and ArtiQ.Spiro are CE-marked Class IIa medical devices under EU MDR 2017/745. The company was acquired by Clario in April 2024.
Differentiator
Problem solved
Functional benefit
Brands
- ArtiQ.PFT: Automated interpretation support software for pulmonary function tests (PFT), providing AI-powered decision support for pulmonologists to diagnose lung diseases faster and more accurately.
- ArtiQ.Spiro
- ArtiQ.QC
- ArtiQ.RBM
Products and services
- ArtiQ.PFT Cloud-based AI software for automated interpretation of pulmonary function tests (PFTs) that provides pulmonologists with diagnostic decision support by predicting probabilities of disease presence across obstructive, restrictive, and mixed lung disease patterns. CE marked as a Class IIa medical device under EU MDR 2017/745. Designed for pulmonologists and respiratory specialists in hospitals and university medical centers.
- ArtiQ.Spiro Automated interpretation support software for spirometry tests that provides feedback on measurement quality and assists in interpretation following international ATS/ERS guidelines. CE marked as Class IIa medical device. Equipment-independent, with integrations available for several spirometry brands. Designed for pulmonologists, GPs, and respiratory specialists performing spirometry.
- ArtiQ.QC AI-based over-reading system for instant spirometry quality control in clinical trials. Validated to be at least as accurate as human over-readers, with 95% agreement for FEV1 and 91% for FVC. Provides real-time feedback to study sites and participants via deep learning algorithms that mimic human visual assessment of spirometry quality. Designed for pharmaceutical sponsors and clinical trial eCOA/ePRO platforms including Clario, NuvoAir, Koneksa, patientMpower, and Zephyr.
- ArtiQ.RBM AI-enabled Risk Based Monitoring solution for clinical trials. Detects sites that could benefit from retraining, proposes specific spirometry aspects to focus on, checks for potential data fraud, and suggests prioritized action points. Delivers actionable RBM reports guiding preventive and corrective actions for spirometry data quality. Designed for pharmaceutical sponsors and contract research organizations managing respiratory trials.
Quantifiable outcome
- ArtiQ.PFT improved diagnostic accuracy of primary diagnosis from 44% to 63% in a study with 19 pulmonologists and 60 retrospective cases.
- +6 more outcomes
Companies that use ArtiQ
Customer profileNamed customers8 records
Segments2 records
Ideal customer profiles2 records
ArtiQ technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability4 records
Feature4 records
ArtiQ partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and secondary.
- ClariocoreIn April 2024, ArtiQ was acquired by Clario, a leading healthcare research and technology company. This acquisition allows ArtiQ to broaden its global reach across clinical trials and sponsors. ArtiQ's technology (ArtiQ.QC) is integrated into Clario's clinical trial platform, enabling AI-driven respiratory solutions for Clario's global pharma sponsor客户.
- AstraZenecacoreArtiQ announced a partnership with AstraZeneca reflecting shared dedication to advancing respiratory research and enhancing quality of life for individuals with lung diseases. The partnership includes AI-enabled spirometry feedback (ArtiQ.QC) and Risk Based Monitoring (ArtiQ.RBM) in AstraZeneca's clinical trials. Also includes the AISAH-COPD project using ArtiQ.Spiro for COPD diagnosis in primary care.
- ZephyrsecondaryArtiQ.QC is integrated with Zephyr's clinical trial platform, enabling AI-based spirometry over-reading for trials run on the Zephyr system.
- NuvoAircoreNuvoAir partnered with ArtiQ to provide AI-based over-reading of spirometry to improve the efficiency of clinical trials. NuvoAir's platform integrates ArtiQ.QC for automated quality assessment of spirometry data collected in decentralized trials.
- patientMpowersecondaryArtiQ and patientMpower joined forces to provide the best quality home spirometry to patients and healthcare professionals, integrating ArtiQ's quality assessment into patientMpower's home monitoring platform.
- Boehringer IngelheimcoreBoehringer Ingelheim and ArtiQ joined forces to help bring specialist-level respiratory expertise to all levels of care, extending AI-powered diagnostics beyond specialist settings.
- Vyaire MedicalcoreVyaire Medical partnered with ArtiQ to distribute ArtiQ.PFT software to hospitals across Europe. Vyaire is a leading manufacturer of respiratory diagnostic equipment, making this partnership a strategic channel distribution arrangement.
- Chiesi GroupcoreThrough the Ai4SPIRO project, Chiesi and ArtiQ demonstrated that AI can assess spirometry quality with high accuracy, offering an alternative or assistance to human over-reading. Chiesi sponsored a validation study comparing ArtiQ.QC against human over-reading, demonstrating 95% agreement for FEV1 and 91% for FVC.
- KoneksacoreKoneksa partnered with ArtiQ to enable real-time evaluation of spirometry data quality using ArtiQ.QC, paired with ArtiQ's RBM reports for both patient-level and site-level intervention. This enables Koneksa's pharma sponsor partners to have confidence in remotely collected pulmonary function data.
- AcertyssecondaryAcertys partnered with ArtiQ to distribute ArtiQ.PFT to the healthcare community, with General Manager André Morias endorsing the technology as part of their vision to bring innovation to healthcare.
Scale indicators8 records
Recent moves7 records
Expansion highlights5 records
ArtiQ competitors and assessment
Company assessmentDirect peers
- NuvoAir: NuvoAir is a digital health company focused on respiratory care and decentralized clinical trials, offering home spirometry and AI-supported monitoring. It is a direct peer to ArtiQ as both are integrated across the same overlapping clinical trial platforms (Koneksa, patientMpower, Zephyr) and compete/collaborate on AI-enabled spirometry over-reading.
- Koneksa: Koneksa is a digital biomarker and decentralized clinical trial platform that partners with ArtiQ on ArtiQ.QC and ArtiQ.RBM. Comparable as a peer in respiratory clinical endpoints and a direct channel partner that competes for similar pharma sponsor budget allocation in respiratory digital biomarkers.
Emerging players
- patientMpower: patientMpower provides digital platforms for home spirometry and patient-reported outcomes, and has a direct partnership with ArtiQ for AI quality assessment. Comparable as a peer in home/respiratory digital endpoints and patient-facing data capture that competes for the same pharma trial integrations.
- Zephyrus / Zephyr (Clinical Trial Platform): The Zephyr clinical trial platform integrates ArtiQ.QC for AI-based spirometry over-reading. Comparable as a peer in decentralized clinical trial platform infrastructure serving respiratory and other indications, overlapping on the same sponsor integrations.
- Biofourmis: Biofourmis is a digital therapeutics and decentralized clinical trial platform with AI-enabled biomarker analytics, having expanded into respiratory and cardiology endpoints. Comparable as a peer in clinical-trial AI for physiological data and adjacent to ArtiQ's respiratory focus.
- Huma (formerly Medopad): Huma is a digital health and decentralized clinical trial platform with regulated Software as a Medical Device products across multiple therapeutic areas. Comparable as a peer in regulated AI/clinical decision-support software for clinical research and healthcare, with broader modality reach than ArtiQ.
Broad incumbents
- Clario: Clario is ArtiQ's parent company (acquired ArtiQ in April 2024) and a leading clinical trial technology and eCOA/ePRO provider serving respiratory and other therapeutic areas. Serves as both parent and broad incumbent peer in clinical trial AI and patient-facing data capture, using ArtiQ.QC within its platform.
- Vyaire Medical: Vyaire Medical is a leading manufacturer of respiratory diagnostic equipment (spirometers, PFT systems) and a European distribution partner for ArtiQ.PFT. Comparable as a broad incumbent in pulmonary function equipment and adjacent AI/interpretation software, with potential to internalize or compete with ArtiQ's interpretation layer.
- ERT (now part of Clario) / eCOA Clinical Trial Platforms: ERT was a leading eCOA provider for clinical trials and is now part of Clario; the broader eCOA/ePRO competitor set represents broad incumbents that embed or compete with ArtiQ.QC-level AI QC for respiratory endpoints, and sit within Clario and competitor portfolios.
- Philips (Respiratory & Sleep / Respironics): Philips is a global medtech incumbent with extensive respiratory diagnostics, sleep, and hospital informatics assets. Comparable as a broad incumbent in respiratory diagnostics and connected-care platforms, with the scale to bundle AI interpretation features that compete with ArtiQ's hospital PFT software.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
ArtiQ social profiles
Digital presenceArtiQ compliance and trust
Trust signalCompliance3 records
ArtiQ financial estimates
Financial estimateRevenue estimate
Valuation estimate
ArtiQ leadership team
Management profileNumber of profiles
Profiles14 records
ArtiQ funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ArtiQ M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ArtiQ
What does ArtiQ do?
ArtiQ develops AI-first software solutions for respiratory diagnostics and clinical research. Its product portfolio includes ArtiQ.PFT and ArtiQ.Spiro (CE-marked Class IIa medical devices that provide automated AI interpretation support for pulmonary function tests and spirometry) and ArtiQ.QC and ArtiQ.RBM (AI-based over-reading and risk-based monitoring software for spirometry quality control in pharmaceutical clinical trials). The software is sold to pulmonologists, hospitals, and pharmaceutical companies, and is embedded into clinical trial eCOA/ePRO platforms through integrations with Clario, NuvoAir, Koneksa, patientMpower, and Zephyr.
Is ArtiQ a public or private company?
ArtiQ is a private company. It is classified as corporate owned and is currently acquired.
When was ArtiQ founded?
ArtiQ was founded in 2019. It employs 11 to 50 people.
Where is ArtiQ based?
ArtiQ is headquartered in Leuven, Belgium, in the Europe region.
How does ArtiQ make money?
Two revenue lines are on record. Software Subscriptions / Licenses (ArtiQ.PFT, ArtiQ.Spiro) is the primary driver. The others are clinical Trial Software (ArtiQ.QC, ArtiQ.RBM).
Who are ArtiQ's main competitors?
Direct peers on record are NuvoAir and Koneksa. Emerging players are patientMpower, Zephyrus / Zephyr (Clinical Trial Platform), Biofourmis and Huma (formerly Medopad). Broad incumbents are Clario, Vyaire Medical, ERT (now part of Clario) / eCOA Clinical Trial Platforms and Philips (Respiratory & Sleep / Respironics).
Does ArtiQ have an API?
No public API is recorded for ArtiQ.
What industry is ArtiQ in?
ArtiQ's product category is AI Medical Device Software (Respiratory Diagnostics & Clinical Trials). Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAKANAC, Pulmonary Function Testing (PFT) & Respiratory Diagnostics. Its NAICS code is 513210 and its SIC code is 7372.